3,394 Shares in Insulet Corporation $PODD Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 3,394 shares of the medical instruments supplier’s stock, valued at approximately $517,000.

Other hedge funds also recently modified their holdings of the company. Empirical Asset Management LLC acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $368,000. Danske Bank A S acquired a new position in Insulet in the second quarter valued at approximately $6,989,000. Diversify Advisory Services LLC bought a new position in Insulet in the second quarter valued at approximately $374,000. Wealthfront Advisers LLC bought a new position in Insulet in the second quarter valued at approximately $392,000. Finally, Meeder Asset Management Inc. acquired a new stake in Insulet during the 2nd quarter worth $94,000.

Analyst Ratings Changes

PODD has been the subject of several recent research reports. Sanford C. Bernstein dropped their target price on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group reduced their price target on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. UBS Group decreased their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Insulet in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 target price on the stock. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Insulet currently has an average rating of “Hold” and an average price target of $195.40.

Insulet Stock Up 0.9%

Shares of NASDAQ:PODD opened at $148.16 on Friday. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The company has a market capitalization of $10.27 billion, a PE ratio of 27.69, a PEG ratio of 1.17 and a beta of 1.10. The company has a 50 day moving average price of $154.67 and a two-hundred day moving average price of $184.81.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the firm posted $1.17 earnings per share. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.